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Background: To investigate the association of a coronary artery disease (CAD) risk SNP rs6903956 with
asymptomatic hyperuricemia (aHU) susceptibility in Han Chinese.
Methods: Two hundred and twenty one patients with aHU and 447 healthy controls were recruited for this study.
SNP rs6903956 were genotyped using TaqMan probe.
Results: The overall genotype and allele frequency distribution of the rs6903956 showed significant difference
between aHU cases and controls (p <0.001 for genotype and allele, respectively). AA genotype of rs6903956 was
significantly associated with aHU (OR = 8.672, 95% CI 2.811-26.753, p <0.001) in our Han Chinese aHU cohort.
Multivariate logistic regression analysis indicated that rs6903956 might be an independent risk factor for aHU
susceptibility (OR = 10.642 [2.671- 42.400], p = 0.001 for codominant model and OR = 9.205 [2.336-36.280], p = 0.002
for recessive model) after adjustment for some well- known CAD risk factors including age, gender, body mass
index, smoking, hypertension, diabetes mellitus, abnormal glycometabolism, lipid abnormality and alcohol intake.
No significant genotype-specific difference in uric acid levels was observed in aHU patients and controls.
Conclusions: Our findings are the first to establish a genetic link of a CAD-associated rs6903956 with aHU in a Han
Chinese population, providing the genetic evidence to support the close relationship between hyperuricemia and CAD.
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Hyperuricemia (HU) is present in 5-30% of the general
population and has been increasing around the world
probably due to prolonged life expectancy, lifestyle and
dietary changes, and the usage of certain drugs [1]. HU
is the most significant risk factor for gout definitely, but
still plays a controversial role in the development of sev-
eral chronic diseases including coronary artery disease
(CAD) [2,3].
Among them, the relation between HU and CAD has
been a topic of much interest in worldwide recently. The
growing numbers of epidemiologic and experimental
evidence have suggested that elevated level of serum uric
is an independent risk factor for CAD incidence and* Correspondence: miaojiazhang@yahoo.com.cn
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unless otherwise stated.mortality [4]. Although how the HU triggers the devel-
opment and progression of CAD remains unclear, endo-
thelial cell dysfunction, vascular smooth muscle cell
proliferation, platelet adhesiveness and renin-angiotensin
system activation caused by high levels of uric acid in
circulation might be the explanation [5].
In addition to dietary and deficiency of the enzyme uri-
case, the varying levels of uric acid in human population
are influenced by genetic factors. To date, Genome-Wide
association (GWA) studies have identified and replicated
28 genetic loci that are strongly associated with serum uric
acid concentrations in European ancestry including 18
new regions in or near TRIM46, INHBB, SFMBT1,
TMEM171, VEGFA, BAZ1B, PRKAG2, STC1, HNF4G,
A1CF, ATXN2, UBE2Q2, IGF1R, etc.[6]. Associations for
many of the 28 loci mentioned above such as ABCG2,
PDZK1, SLC16A9, SLC2A9,SLC22A11, SLC22A12 etc.
were of similar magnitude in individuals of non-EuropeanThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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found that SNP rs1333049 on chromosome 9p21, SLC2A9
and hURAT1 contributed to the HU susceptibility in Han
Chinese populations [10-12]. Interestingly, genetic varia-
tions in multiple HU risk genes included ABCG2, PDZK1,
SLC22A12 have also been linked to plasma lipoprotein (a)
levels or hypertension, two most significant known risk
factors for CAD [13-15]. These findings lead us to suspect
that HU or dyslipidemia may at least partly share the com-
mon genetic background with CAD.
Recently, GWAS study identified that a novel strong
risk locus of rs6903956 in C6orf105 contributed to CAD
susceptibility in Han Chinese (p = 4.87 × 10−12, odds ra-
tio = 1.51) [16]. We therefore test whether this CAD-
associated SNP is also a genetic signal for HU risk in
our Chinese Han cohort.
Results
Characteristic of aHU cases and controls samples
The clinical features of individuals recruited in the study
are summarized in Table 1. aHU patients had signifi-
cantly increased proportions of males compared with
controls. The frequency of abnormalities in serum levels
of total cholesterol (TC), triglyceride (TG), blood glu-
cose, BMI (Body Mass Index) and hypertension are
higher in aHU than those in controls (Table 1, p < 0.05).
Age and C-reactive protein was equally distributed be-
tween the two groups (Table 1).Table 1 Demographic and clinical characteristics of the study
Category Cases (n = 221)
n
Age (mean ± SD) 51.9 ± 13.6
Gender Males 158
Females 63







Diabetes mellitus Yes 3
No 218
Abnormal glycometabolism Yes 77
No 144
Lipid abnormality Yes 99
No 122
C-reactive protein (mg/L) 4.04 ± 4.38
Uric acid level (μmol/L) 467.4 ± 56.9
acontinuous variables were evaluated using Student’s t-test; categorical variables weAssociation of rs6903956 with aHU susceptibility
In both patient and control groups, genotype and allele
frequencies did not deviate significantly from those ex-
pected from the Hardy–Weinberg equilibrium. The al-
lelic and genotypic frequencies of rs6903956 are shown
in Table 2. Compared with healthy controls, aHU have a
higher allelic frequency of A allele (0.176 versus 0.068,
p <0.001). aHU also have a higher genotypic frequency
for the homozygous AA genotype than healthy controls
(0.063 versus 0.009, p <0.001). In codominant, dominant
and recessive model, rs6903956 AA genotype was signifi-
cantly associated with aHU susceptibility in our cohort
(OR = 8.672 [2.811-26.753], p <0.001 for codominant
model; OR = 2.782 [1.861-4.159], p <0.001 for dominant
model; OR = 7.473 [2.430-22.983], p <0.001 for recessive
model) (Table 3).
Since aHU patients had higher frequency of abnormal-
ity in serum levels of TGs, TC and blood glucose com-
pared to controls in our patients, multivariate logistic
regression analysis was used to exclude the effect of con-
founding factors on genetic association. rs6903956 AA
genotype still conferred the strong association with aHU
in our samples after adjustment for those well-known
CAD risk factors including age, gender, BMI, smoking,
hypertension, diabetes mellitus, abnormal glycometabo-
lism, lipid abnormality and alcohol intake, suggesting
rs6903956 might be an independent risk factor for aHU
susceptibility (Table 3).population
Controls (n = 446) pa
% n %
51.3 ± 12.5 0.544
71.5 184 41.3 <0.001
28.5 262 58.7
24.5 ± 3.2 <0.001
47.5 124 27.8 <0.001
52.5 322 72.2
34.4 67 15.0 <0.001
65.6 379 85.0
40.3 56 12.6 <0.001
59.7 390 87.4
1.4 0 0.0 0.036
98.6 446 100.0
34.8 29 6.5 <0.001
65.2 417 93.5
44.8 3 0.7 < 0.001
55.2 443 99.3
3.84 ± 3.26 0.527
269.6 ± 56.2 < 0.001
re Chi-square test.
Table 2 Genotypic and allelic frequencies of SNP rs6903956 in aHU cases and controls
Group Genotype (%) Allele (%)
GG GA AA p G A OR (95% CI) p
Cases 157(71.1) 50(22.6) 14(6.3) <0.001 364(82.4) 78(17.6) 2.919(2.043-4.171) <0.001
Controls 389(87.2) 53(11.9) 4(0.9) 831(93.2) 61(6.8)
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We further address whether genetic variation of rs6903956
could influence uric acid levels. No significant genotype-
specific difference in uric acid levels was observed in aHU
patients (Figure 1) and healthy controls (Figure 2), which
might be attributed to the narrow range of uric acid levels
in our study population (median = 453.6 μmol/L; 25%
to 75% percentile = 431.5 μmol/L to 494.9 μmol/L in
aHU, median = 264.9 μmol/L; 25% to 75% percentile =
224.5 μmol/L to 308.75 μmol/L in controls) or the insuffi-
cient power.
Discussion
Elevated levels of serum uric acid have been suggested as
an independent risk factor for CAD [17]. Previously GWAS
study has confirmed the genetic association of rs6903956
with CAD in Han Chinese population [16]. We suspect that
loci linked to CAD may also contribute to the pathogenesis
of hyperuricemia or gout. We tested the association of this
CAD-associated locus with aHU in present study. Our data
are first to indicate that rs6903956 is contributed to aHU
susceptibly in our Chinese Han population, providing the
potential genetic evidence to support the close relationship
between serum uric acid and CAD.
Considering these aHU patients have higher proportions
of dyslipidemia, hyperglycemia and overweight than those
in controls [18], it is important to clarify whether this locus
is a real genetic signal for aHU or just is linked to certain of
CAD risk factor. By multivariate logistic regression analysis,
our data showed that AA genotype still remained the
strong association with HU after adjustment for some well-
known CAD risk factors included age, gender, BMI, smok-
ing, blood pressure, blood glucose, cholesterol and alcoholTable 3 The association of SNP rs6903956 genotype with aHU
Model Genotype Cases (n = 221) Controls (n = 446)
n % n %
codominant GG 157 71.1 389 87.2
GA 50 22.6 53 11.9
AA 14 6.3 4 0.9
dominant GG 157 71.0 389 87.2
GA + AA 64 29.0 57 12.8
recessive GG + GA 207 93.7 442 99.1
AA 14 6.3 4 0.9
ausing univariate logistic regression analysis; badjusted for age, gender, BMI, smokin
abnormality, drinking. Odds ratio (95% confidence interval) was expressed for the rconsumption, suggesting rs6903956 might be an independ-
ent risk factor for aHU susceptibility. Similarly, Wang et al.
reported a CAD-associated SNP rs1333049 at 9p21 is
linked with gout susceptibility [10], which supported our
data that hyperuricemia might at least partly share the
common genetic background with CAD.
The rs6903956 is located in intron 1 of C6orf105.
C6orf105 is mainly expressed in heart, stomach, skin,
kidney, endothelia cell and leukocytes and its function
remains unclear. Interestingly, recently study found that
C6orf105 could encode a novel uncharacterized protein
ADTRP to regulate androgen-enhanced tissue factor
pathway inhibitor (TFPI) expression in cultured endo-
thelial cells. TFPI is a key natural inhibitor of coagula-
tion and play an important role in maintaining normal
blood flow and endothelial cell function [19]. The defi-
ciency of TFPI could promote atherosclerosis and throm-
bosis in mice highlighted a protecting role of TFPI in the
pathogenesis of CAD [20]. Given the minor risk allele A of
rs6903956 has been suggested to confer a decreased
C6orf105 mRNA expression in CAD patients [16], it is pos-
sible that genetic variant of C6orf105 hence affect TFPI ex-
pression by altering ADTRP, resulting in endothelial cell
dysfunction and abnormality of coagulation, which might
explain rs6903956 contribute to CAD susceptibility. How-
ever, the mechanisms involved in the association of
rs6903956 and aHU remains unclear. The heritability of
serum urate concentrations is estimated at 40 − 70% [21].
Previous GWAS have so far identified more than 20 gen-
omic loci associated with urate concentrations and gout,
which explained about 5–6% of variance in serum urate
concentrations [6]. Unfortunately, we failed to find a gen-
etic association of rs6903956 with uric acid levels, theOR (95% CI)a pa Adjusted OR
(95% CI)b
pb
1.000 (Reference) 1.000 (Reference)
2.337(1.523-3.588) <0.001 2.411(1.321-4.402) 0.004
8.672 (2.811-26.753) <0.001 10.642(2.671-42.400) 0.001
1.000 (Reference) 1.000 (Reference)
2.782(1.861-4.159) <0.001 2.988(1.717-5.202) <0.001
1.000 (Reference) 1.000 (Reference)
7.473(2.430-22.983) <0.001 9.205 (2.336-36.280) 0.002
g, hypertension, diabetes mellitus, abnormal glycometabolism, lipid
isk of the other genotype when GG or GG+GA genotype was referenced.
Figure 1 The uric acid levels of genotype of rs6903956 in cases. There
is no difference on uric acid levels among the three genotypes of rs6903956
using ANOVA (479.4 ± 75.5 μmol/L for AA-carriers vs. 471.2 ± 55.0 μmol/L
for AG-carriers, vs. 465.1 ± 55.9 μmol/L for GG-carriers, p > 0.05).
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might be an explanation. Further studies are needed to clar-
ify the real role of C6orf105 on uric acid production and
transport.
Half of aHU patients in current study are >52 years who
had been exposed to a greater cardiovascular risk but still
lack of any clinical symptom of CAD, supporting that these
patients are a good asymptomatic hyperuricemia cohort to
study the genetic link between HU and CAD; however, weFigure 2 The uric acid levels of genotype of rs6903956 in controls.
There is no difference on uric acid levels among the three genotypes
of rs6903956 using ANOVA (261.3 ± 95.2 μmol/L for AA-carriers vs.
257.5 ± 57.2 μmol/L for AG-carriers, vs. 271.3 ± 55.5 μmol/L for
GG-carriers, p > 0.05).could not exclude the possibility that some subclinical
CAD patients were still mixed in this study. Therefore, fur-
ther prospective studies in a larger population with longer
follow-up are needed to confirm the genetic link between
HU and CAD and the potential role of this SNP in acid
homeostasis.Methods
Patients and controls
To explore the potential genetic link between HU and
CAD, a total of 221 asymptomatic hyperuricemia (aHU)
patients and 447 health volunteers from Gaoyou rural
district of Jiangsu Province, China were recruited for this
study. aHU were defined as: 1) people with serum uric
acid levels >420 μmol/L in man and post-menopausal
woman, and as >350 μmol/L in premenopausal woman;
2) these patients never suffered from gout, and no self-
reported history of CAD and/or any symptom and sign
of CAD after carefully physical examination and med-
ical history inquiry [10]. Healthy controls were defined
as individuals without hyperuricemia, CAD and signifi-
cant abnormalities in plasma glucose, total cholesterol
(TC) and triglycerides (TG) levels. The smoker was de-
fined as people who consumed at least one cigarette a
day for more than a year. Drinking was defined as those
who reported frequent or daily alcohol consumption.
Abnormal glycometabolism was defined as fasting
blood glucose ≥6.0 mmol/L. Lipid abnormality was de-
fined as abnormal levels of more than one of the
following lipid fraction: triglycerides ≥2.25 mmol/L,
total cholesterol ≥6.25 mmol/L, high density lipopro-
tein ≤0.9 mmol/L, low density lipoprotein ≥4.11 mmol/ L.
Persons with hypertension history and/or receiving anti-
hypertensive medication were considered hypertensive.
Individuals with diabetes mellitus history and/or use
hypoglycemic medications were defined as diabetes melli-
tus. CAD was defined by the self-reported history and/or
receiving the treatment of CAD. The Ethics committee of
the First Affiliated Hospital of Nanjing Medical University
approved the study protocol and informed consent was ob-
tained from each of the eligible participants before recruit-
ment. The study was in accordance with the principles of
the current version of the Declaration of Helsinki. All par-
ticipants were measured and recorded for body mass index
(BMI), plasma levels of blood glucose, creatinine, uric acid,
TC and TG. All biochemical analysis was performed in the
central laboratory of the First Affiliated Hospital of Nanjing
Medical University.Genotyping
Genomic DNA was obtained from the peripheral blood
leukocytes using the PureGene DNA Blood Kit (QIAGEN,
Germany). The SNP rs6903956 was genotyped by TaqMan
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City, CA, USA). The reaction mix was made from 20 ×
SNP genotyping assay, 2 × TaqMan Genotyping Master
Mix, no AmpErase UNG, and DNA-free water. The final
reaction volume per well is 5 μL containing 1 × SNP geno-
typing assay, 1 × TaqMan Genotyping Master Mix and
about 20 ng DNA for a 384-well plate. The PCR reaction
was performed according to the manufacturer’s protocol
using the Applied Biosystems 7900HT Fast Real-Time
PCR System: Enzyme Activation at 95°C for 10 minutes;
denature at 95°C for 15 seconds, extension at 60°C for
1 minute, a total of 40 cycles. Post-PCR plate read and
analysis were performed by Sequence Detection System
software version 2.4 (Applied Biosystems).Statistical analysis
Genotypes were tested for Hardy-Weinberg equilibrium
among all participants using a Chi-square test. Allele and
genotype frequencies of rs6903956 were obtained by direct
counting and the distributions comparison was performed
by the Chi-square test. Differences in selected demographic
continuous variables among groups were evaluated by one-
way analysis of variance (ANOVA) or the Kruskal-Wallis H
test. Categorical variables including sex, smoking status, al-
cohol consumption status, hypertension status, diabetes
status were compared among the genotypes of rs6903956
using a Chi-square test. The association of rs6903956 geno-
type and aHU risk were estimated using codominant model
(compared three genotype), dominant model (defined as
GG vs. GA+AA) and recessive model (defined as GG+
GA vs. AA), respectively. Odds ratios (OR) with their 95%
confidence intervals (CI) were reported. A multivariate lo-
gistic regression analysis was used for association analyses
with adjustments for age, gender, BMI, smoking, hyperten-
sion, and diabetes mellitus. P-value < 0.05 was considered
statistically significant.
The statistical power calculation for the case–control
analysis was performed using Quanto software (http://
hydra.usc.edu/gxe/_vti_bin/shtml.dll/request.htm). Con-
sidering rs6903956 minor allele frequency of 10% that
was obtained in Han Chinese CAD patients [16], our
sample size had 90% power (α = 0.05) to detect genetic
effects with an OR ≥1.5 (estimated hyperuricemia preva-
lence in the background population = 5-30%).Competing interests
The authors declare that they have no competing interests.Authors’ contributions
JFM, WFT, YJZ and FW collected aHU and HC samples and extracted DNA.
JFM performed the genotyping experiment. JFM, WFT and MJZ conducted
analyzed data. YJZ, FW and XLL helped to conduct research and analyze
data. JFM and WFT designed the research and wrote paper. All authors read
and approved the final manuscript.Acknowledgments
We wish to thank Dr. Haifeng Zhang and all the investigators participated in the
epidemiological investigation in Gaoyou city for valuable supports and
assistances. This study was financially supported by The National Natural
Science Foundation of China (NSFC) (30701129,30901332,81172845, 81273294),
National Natural Science Foundation of Jiangsu province (BK2011851,
BK2012875) , the Key Project of the Natural Science Foundation of Jiangsu
Province, China (No.BK2011851 and BK2012875), the special project of clinical
medicine from Jiangsu province: BL2013034, Department of Science and
Technology of Jiangsu Province, China (BE2009613) and grant from
International League of Associations for Rheumatology. W.T is recipient of a
scholarship from Asia Pacific League of Associations for Rheumatology (APLAR).
Author details
1Department of Rheumatology, the First Affiliated Hospital of Nanjing
Medical University, Nanjing, Jiangsu, China. 2Department of Cardiology, the
First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
3Current affiliation: Department of Rheumatology, the Fourth Affiliated
Hospital of Nantong Medical College, Yancheng, Jiangsu, China.
Received: 5 October 2014 Accepted: 25 March 2015References
1. So A, Thorens B. Uric acid transport and disease. J Clin Invest.
2010;120:1791–9.
2. Krishnan E, Pandya BJ, Chung L, Dabbous O. Hyperuricemia and the risk for
subclinical coronary atherosclerosis–data from a prospective observational
cohort study. Arthritis Res Ther. 2011;13:R66.
3. Duran M, Kalay N, Akpek M, Orscelik O, Elcik D, Ocak A, et al. High levels of
serum uric acid predict severity of coronary artery disease in patients with
acute coronary syndrome. Angiology. 2012;63:448–52.
4. Clarson L, Chandratre P, Hider S, Belcher J, Heneghan C, Roddy E, et al.
Increased cardiovascular mortality associated with gout: a systematic review
and meta-analysis. Eur J Prev Cardiol. 2013. [Epub ahead of print].
5. Kanellis JKD. Uric acid as a mediator of endothelial dysfunction,
inflammation, and vascular disease. Semin Nephrol. 2005;25:39–42.
6. Köttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, et al.
Genome-wide association analyses identify 18 new loci associated with
serum urate concentrations. Nat Genet. 2013;45:145–54.
7. Yamagishi K, Tanigawa T, Kitamura A, Köttgen A, Folsom AR, Iso H. The
rs2231142 variant of the ABCG2 gene is associated with uric acid levels and
gout among Japanese people. Rheumatology (Oxford). 2010;49:1461–5.
8. Anzai N, Miyazaki H, Noshiro R, Khamdang S, Chairoungdua A, Shin HJ, et al.
The multivalent PDZ domain-containing protein PDZK1 regulates transport
activity of renal urate-anion exchanger URAT1 via its C terminus. J Biol
Chem. 2004;279:45942–50.
9. Lee YH, Song GG. Pathway analysis of genome-wide association studies on
uric acid concentrations. Hum Immunol. 2012;73:805–10.
10. Wang B, Meng D, Wang J, Liu S, Zhou S, Miao Z, et al. Genetic association
of polymorphism rs1333049 with gout. Rheumatology (Oxford).
2011;50:1559–61.
11. Guan M, Zhou D, Ma W, Chen Y, Zhang J, Zou H. Association of an intronic
SNP of SLC2A9 gene with serum uric acid levels in the Chinese male Han
population by high-resolution melting method. Clin Rheumatol. 2011;30:29–35.
12. Li C, Han L, Levin AM, Song H, Yan S, Wang Y, et al. Multiple single
nucleotide polymorphisms in the human urate transporter 1 (hURAT1) gene
are associated with hyperuricaemia in Han Chinese. J Med Genet.
2010;47:204–10.
13. Luke MM, Kane JP, Liu DM, Rowland CM, Shiffman D, Cassano J, et al. A
polymorphism in the protease-like domain of apolipoprotein(a) is associated
with severe coronary artery disease. Arterioscler Thromb Vasc Biol.
2007;27:2030–6.
14. Silver DL, Wang N, Vogel S. Identification of small PDZK1-associated protein,
DD96/MAP17, as a regulator of PDZK1 and plasma high density lipoprotein
levels. J Biol Chem. 2003;278:28528–32.
15. Shafiu M, Johnson RJ, Turner ST, Langaee T, Gong Y, Chapman AB, et al.
Urate transporter gene SLC22A12 polymorphisms associated with obesity
and metabolic syndrome in Caucasians with hypertension. Kidney Blood
Press Res. 2012;35:477–82.
Meng et al. Lipids in Health and Disease  (2015) 14:33 Page 6 of 616. Wang F, Xu CQ, He Q, Cai JP, Li XC, Wang D, et al. Genome-wide association
identifies a susceptibility locus for coronary artery disease in the Chinese
Han population. Nat Genet. 2011;43:345–9.
17. Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ. The
role of uric acid in the pathogenesis of human cardiovascular disease.
Heart. 2013;99:759–66.
18. Zhang JW, He LJ, Cao SJ, Yang Q, Yang SW, Zhou YJ. Association of serum
uric acid and coronary artery disease in premenopausal women. PLoS One.
2014;9:e106130.
19. Lupu C, Zhu H, Popescu NI, Wren JD, Lupu F. Novel protein ADTRP
regulates TFPI expression and function in human endothelial cells in normal
conditions and in response to androgen. Blood. 2011;118:4463–71.
20. Westrick RJ, Bodary PF, Xu Z, Shen YC, Broze GJ, Eitzman DT. Deficiency of
tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in
mice. Circulation. 2001;103:3044–6.
21. Nath SD, Voruganti VS, Arar NH, Thameem F, Lopez-Alvarenga JC, Bauer R.
Genome scan for determinants of serum uric acid variability. J Am Soc
Nephrol. 2007;18:3156–63.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
